Raslone 1 Tablet containing Rasagiline is used for the management of Parkinson’s disease. It helps in improving motor symptoms and supporting better movement control.
Rasagiline works by inhibiting monoamine oxidase-B (MAO-B), which increases dopamine availability in the brain and helps improve neurological function.
The tablet is widely prescribed in neurology practice for long-term management of Parkinson’s disease, leading to consistent demand and repeat usage.
With increasing awareness of neurological care and rising prevalence of Parkinson’s disease, this product offers strong business potential for retailers and distributors. Its long-term therapy requirement, steady prescription demand, and specialized neuro segment usage make it a reliable product for consistent sales and growth in the neurology category.
Some patients may experience headache, dizziness, nausea, insomnia, dry mouth, or joint pain. Rarely, hallucinations, blood pressure fluctuations, or serotonin syndrome may occur, especially when used with certain antidepressants or interacting medicines.
Raslone 1 Tablet is indicated for the treatment of Parkinson’s disease, either as monotherapy in early-stage disease or in combination with other anti-Parkinson medications. It helps reduce tremors, rigidity, slowness of movement, and improves overall motor performance and daily functioning.
This medicine should be used under medical supervision. Patients should inform their healthcare provider about all current medications to avoid serious drug interactions. Use cautiously in patients with liver disorders and follow dietary precautions if advised.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.